Evaluation of Polymyxin B as a Novel Vaccine Adjuvant and Its Immunological Comparison with FDA-Approved Adjuvants. [PDF]
Gulani M +7 more
europepmc +1 more source
Extended dosing intervals enhance the durability of a self-amplifying mRNA vaccine against pandemic H5N1 influenza: a randomized, observer-blind, dose-finding Phase I study. [PDF]
Pragalos AA +9 more
europepmc +1 more source
Skeletal muscle as a dynamic immunological niche for vaccination. [PDF]
Noureddine M, Schotsaert M.
europepmc +1 more source
Editorial: Innovative adjuvant strategies: enhancing vaccine efficacy through transdisciplinary approaches. [PDF]
Angulo C, Parola AD, Ramos Vega AA.
europepmc +1 more source
Cytomegalovirus Vaccines in Transplantation: History, Hurdles, and Hope. [PDF]
Goodwin ML, Limaye AP, Heldman MR.
europepmc +1 more source
MF59-adjuvanted A/Astrakhan influenza vaccine induces cross-neutralizing H5N1 antibodies in ferrets against circulating clade 2.3.4.4b viruses. [PDF]
Segovia K +12 more
europepmc +1 more source
A novel calcium influx inducer and a TLR7 agonist are synergistic co-adjuvants that enhance cross-reactive immunity against influenza in young and aged mice. [PDF]
Yokoyama Y +13 more
europepmc +1 more source
Maternal influenza vaccination during the first trimester of pregnancy and risk for birth defects: an updated systematic review and meta-analysis. [PDF]
Wu Y, Liu C, Qian X, Zhou Y, Xiong Y.
europepmc +1 more source
Antineuraminidase Antibody Responses in Older Adults After Consecutive Vaccinations With Enhanced Influenza Vaccines: A Randomized Controlled Trial. [PDF]
Daulagala P +13 more
europepmc +1 more source
Application of a small molecule calcium influx inducer as a vaccine adjuvant: enhancing Th2-biased immune responses. [PDF]
Yokoyama Y +13 more
europepmc +1 more source

